De-identified Health Data Market, By Type of Data (Clinical Data, Genomic Data, Patient Demographics, Prescription Data, Claims Data, Behavioral Data, Wearable and Sensor Data, Survey and Patient-Reported Data, Imaging Data , Laboratory Data, Social Deter

De-identified Health Data Market, By Type of Data (Clinical Data, Genomic Data, Patient Demographics, Prescription Data, Claims Data, Behavioral Data, Wearable and Sensor Data, Survey and Patient-Reported Data, Imaging Data , Laboratory Data, Social Determinants of Health (SDOH) Data, and Others), By Application (Clinical Research and Trials, Public Health, Precision Medicine, Health Economics and Outcomes Research (HEOR), Population Health Management, Drug Discovery and Development, Healthcare Quality Improvement, Insurance Underwriting and Risk Assessment, and Others), By End User (Pharmaceutical Companies, Biotechnology Firms, Healthcare Providers, Insurance Companies/Healthcare Payers, Research Institutions, Government Agencies, and Others), By Geography (North America, Latin America, Asia Pacific, Europe, Middle East, and Africa)

De-identified health data market growth is driven by increasing research and development activities for drug discovery and precision medicine. De-identification ensures patient privacy and confidentiality by removing identifiers such as name, date of birth, social security number, and others from health data sets. This allows researchers and life science companies to utilize large pools of health data for developing novel therapies and epidemiological studies without compromising on ethics. As digitization of health records accelerates across the world, there will be increase in amount of de-identified data available for secondary usage.

Market Dynamics

Rising focus on value-based care, personalization of treatment, and growth of digital health startups can boost demand for de-identified health data globally. However, lack of data standardization and ambiguity over intellectual property rights can hamper the market potential. Development of advanced analytics capabilities offers an opportunity for players to unlock deeper insights from pooled data assets. Growing open data sharing initiatives by governments can widen the access to these data sets. The U.S. government has launched initiatives like Data.gov and HealthData.gov that offers open access to a wide range of health-related datasets to encourage transparency and innovation in public health research.

Key features of the study

• This report provides in-depth analysis of the global de-identified health data market, and provides market size (USD Bn) and compound annual growth rate (CAGR%) for the forecast period (2024–2031), considering 2023 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global de-identified health data market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include IQVIA, Oracle (Cerner Corporation), Merative (Truven Health Analytics), Optum, Inc., BioTelemetry, Inc., Flatiron Health, Veradigm LLC, Medidata Solutions, Evidation Health, Inc., Komodo Health, Inc., Sundown Solutions, LLC, Clarify Health Solutions, Akrivia Health, Satori Cyber Ltd., Tempus, nference, Ciox Health, HealthVerity, Zebra Medical Vision, and Huma Therapeutics
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• Global de-identified health data market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global de-identified health data market

Market Segmentation

• Type of Data Insights (Revenue, USD Bn, 2019 - 2031)
• Clinical Data
• Genomic Data
• Patient Demographics
• Prescription Data
• Claims Data
• Behavioral Data
• Wearable and Sensor Data
• Survey and Patient-Reported Data
• Imaging Data
• Laboratory Data
• Social Determinants of Health (SDOH) Data
• Others
• Application Insights (Revenue, USD Bn, 2019 - 2031)
• Clinical Research and Trials
• Public Health
• Precision Medicine
• Health Economics and Outcomes Research (HEOR)
• Population Health Management
• Drug Discovery and Development
• Healthcare Quality Improvement
• Insurance Underwriting and Risk Assessment
• Others
• End User Insights (Revenue, USD Bn, 2019 - 2031)
• Pharmaceutical Companies
• Biotechnology Firms
• Healthcare Providers
• Insurance Companies/Healthcare Payers
• Research Institutions
• Government Agencies
• Others
• Regional Insights (Revenue, USD Bn, 2019 - 2031)
• North America
• U.S.
• Canada
• Latin America
• Brazil
• Argentina
• Mexico
• Rest of Latin America
• Europe
• Germany
• U.K.
• Spain
• France
• Italy
• Russia
• Rest of Europe
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• ASEAN
• Rest of Asia Pacific
• Middle East
• GCC Countries
• Israel
• Rest of Middle East
• Africa
• South Africa
• North Africa
• Central Africa
• Key Players Insights
• IQVIA
• Oracle (Cerner Corporation)
• Merative (Truven Health Analytics)
• Optum, Inc.
• BioTelemetry, Inc.
• Flatiron Health
• Veradigm LLC
• Medidata Solutions
• Evidation Health, Inc.
• Komodo Health, Inc.
• Sundown Solutions, LLC
• Clarify Health Solutions
• Akrivia Health
• Satori Cyber Ltd.
• Tempus
• nference
• Ciox Health
• HealthVerity
• Zebra Medical Vision
• Huma Therapeutics